Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

Prior treatment

• Previous liver transplantation;
• Previous history of severe mental illness;
• Active bleeding or coagulation abnormalities, bleeding tendency or receiving thrombolytic, anticoagulant or antiplatelet therapy;

Other illness

• History of other malignancies;
• Uncontrollable hepatic encephalopathy, hepatorenal syndrome, ascites, pleural effusion or pericardial effusion;

Other

• Pathologically confirmed diagnosis of fibrolamellar HCC, sarcomatoid HCC, hepatocellular carcinoma-intrahepatic cholangiocarcinoma (HCC-ICC) mixed type;
• Other reasons were judged by the investigator to be unable to enroll.

• 18 years or older.
• HCC was diagnosed according to the Criteria for Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) and American Association for the Study of Liver Diseases (AASLD) criteria.
• Classified as stage C according to the Barcelona Clinic Liver Cancer (BCLC) staging system.
• A dominant mass in theliver with or without extrahepatic oligometastasis, which was defined as up to three metastatic lesions in up to two organs with the largest diameter of≤3 cm.
• No prior treatment for HCC.
• At least one measurable target lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST).
• Performance status (PS) ECOG score ≤1.
• Child-Pugh score ≤7.
• Subjects voluntarily participate in this study, and sign the informed consent form, cooperate with the follow-up
• Adequate organ function, defined as: Hb ≥ 90 g/dL; Neu ≥ 1.5 x 10 \^ 9/L; PLT ≥ 75 x 10 \^ 9/L; ALB ≥2.8 g/dL; TBIL ≤2 times the upper limit of normal; AST and ALT ≤ 3 times the upper limit of normal; Cre ≤1.5 x upper limit of normal; APTT≤1.5 times the upper limit of normal.